SER — Serina Therapeutics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1708599 ·
Last close
$2.09
Market Cap
$53.09M
52W High
$5.83
52W Low
$1.22
ADV30
58,900
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,784,000 | -6,356,000 | 25,814,000 | 23,024,000 | 7,084,000 |
| Mar 2026 | 0 | — | -6,280,000 | -6,898,000 | 27,299,000 | 24,526,000 | 9,671,000 |
| Dec 2025 | 0 | — | -6,207,000 | -3,336,000 | 6,951,000 | 3,056,000 | 6,988,000 |
| Sep 2025 | 0 | — | -6,392,000 | -4,585,000 | 12,413,000 | 8,620,000 | 10,819,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,201,000
Investing CF
$-84,000
Financing CF
$38,552,000
CapEx
$-43,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.18
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-70,398,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-20,864,000
Pretax Income TTM
$-21,266,000
Interest Exp TTM
$402,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-25,587,000
Free Cash Flow
$-12,350,875
Enterprise Value
$37,119,052
Total Cash
$23,024,000
Total Debt
$3,754,000
Shares Out
25,400,473
Trailing EPS
$-1.87
Book Value
$0.74
ROE
-207.9%
ROA
-92.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,022,000 | -19,182,000 | 6,951,000 | 6,988,000 | -37,000 | -17,955,000 |
| Dec 2024 | 0 | -17,048,000 | -11,141,000 | 6,724,000 | 6,216,000 | 641,000 | -17,137,000 |
| Dec 2023 | 3,000,000 | -3,129,000 | 5,269,000 | 8,968,000 | 41,262,000 | -32,294,000 | -2,476,000 |
| Dec 2022 | 500,000 | -2,270,368 | -2,682,108 | 858,042 | 38,636,203 | -37,778,161 | -2,075,624 |
TTM Snapshot
Revenues TTM
$43,000
NetIncome TTM
$-1,651,000
OpCashFlow TTM
$0
Assets (Latest)
$6,951,000
Forward EPS
$-1.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $55.06M | $0.29 | — |
| CLNN | Clene Inc. | $55.25M | $4.30 | — |
| ANVS | Annovis Bio, Inc. | $55.81M | $1.31 | — |
| LITS | Lite Strategy, Inc. | $49.00M | $1.44 | — |
| ELTX | Elicio Therapeutics, Inc. | $48.36M | $1.84 | — |
News headlines (Yahoo Finance, 1h cache)
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
2026-09-23 20:18 · Yahoo
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 20:05 · Yahoo
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
2026-09-09 11:45 · Yahoo
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 20:15 · Yahoo
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-07-23 10:00 · Yahoo
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
2026-07-22 20:30 · Yahoo
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
2026-06-30 13:01 · Yahoo
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
2026-04-07 10:00 · Yahoo
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
2026-04-02 20:13 · Yahoo
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
2026-07-24 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.